keyword
MENU ▼
Read by QxMD icon Read
search

Phosphate binders

keyword
https://www.readbyqxmd.com/read/29780106/a-survey-of-drug-burden-in-patients-undergoing-maintenance-hemodialysis-in-japan
#1
Yuko Iwashita, Masaki Ohya, Satoko Kunimoto, Yu Iwashita, Toru Mima, Shigeo Negi, Takashi Shigematsu
Objective This report presents a part of a survey pertaining to drug burden in maintenance hemodialysis patients in Japan. Methods A patient-reported questionnaire-based survey was conducted from September to November 2016 in six regions in Japan. Patients or Materials A total of 700 patients (50-79 years old) on maintenance hemodialysis for >3 years and members of the Japan Association of Kidney Disease Patients (JAKDP) were provided with the questionnaire. They were randomly selected using stratified sampling according to patient distribution observed from the Japanese Society for Dialysis Therapy Renal Data Registry (JSDT JRDR)...
May 18, 2018: Internal Medicine
https://www.readbyqxmd.com/read/29733462/current-and-potential-therapeutic-strategies-for-the-management-of-vascular-calcification-in-patients-with-chronic-kidney-disease-including-those-on-dialysis
#2
REVIEW
Irene Ruderman, Stephen G Holt, Tim D Hewitson, Edward R Smith, Nigel D Toussaint
Patients with CKD have accelerated vascular stiffening contributing significantly to excess cardiovascular morbidity and mortality. Much of the arterial stiffening is thought to involve vascular calcification (VC), but the pathogenesis of this phenomenon is complex, resulting from a disruption of the balance between promoters and inhibitors of calcification in a uremic milieu, along with derangements in calcium and phosphate metabolic pathways. Management of traditional cardiovascular risk factors to reduce VC may be influential but has not been shown to significantly improve mortality...
May 7, 2018: Seminars in Dialysis
https://www.readbyqxmd.com/read/29706161/the-epigenetic-clock-at-birth-associations-with-maternal-antenatal-depression-and-child-psychiatric-problems
#3
Anna Suarez, Jari Lahti, Darina Czamara, Marius Lahti-Pulkkinen, Anna K Knight, Polina Girchenko, Esa Hämäläinen, Eero Kajantie, Jari Lipsanen, Hannele Laivuori, Pia M Villa, Rebecca M Reynolds, Alicia K Smith, Elisabeth B Binder, Katri Räikkönen
OBJECTIVE: Maternal antenatal depression may compromise the fetal developmental milieu and contribute to individual differences in aging and disease trajectories in later life. We evaluated the association between maternal antenatal depression and a novel biomarker of aging at birth, namely epigenetic gestational age (GA) based on fetal cord blood methylation data. We also examined whether this biomarker prospectively predicts and mediates maternal effects on early childhood psychiatric problems...
May 2018: Journal of the American Academy of Child and Adolescent Psychiatry
https://www.readbyqxmd.com/read/29691773/etelcalcetide-for-treating-secondary-hyperparathyroidism-an-evidence-review-group-evaluation-of-a-nice-single-technology-appraisal
#4
Micah Rose, Jonathan Shepherd, Petra Harris, Karen Pickett, Joanne Lord
The manufacturer of the calcimimetic drug etelcalcetide was invited to make an evidence submission as part of the National Institute for Health and Care Excellence (NICE) Single Technology Appraisal (STA) programme. Within this submission, they reported evidence on the clinical and cost effectiveness of etelcalcetide for the treatment of secondary hyperparathyroidism (SHPT) in patients with chronic kidney disease (CKD) on haemodialysis. The Southampton Health Technology Assessments Centre (SHTAC), part of the Wessex Institute at the University of Southampton, was the independent Evidence Review Group (ERG) commissioned to appraise the company's submission...
April 25, 2018: PharmacoEconomics
https://www.readbyqxmd.com/read/29682371/colonic-mucosal-ulceration-and-gastrointestinal-bleeding-associated-with-sevelamer-crystal-deposition-in-a-patient-with-end-stage-renal-disease
#5
Sudheer Nambiar, Unnikrishnan Kunjan Pillai, Joe Devasahayam, Tony Oliver, Asha Karippot
End stage renal disease (ESRD) population account for 1.9 per patient year of hospital admissions annually. ESRD population are at increased risk of bleeding secondary to use of anticoagulation during hemodialysis and uremia induced platelet dysfunction. Gastrointestinal bleeding accounts for 3-7% of all deaths in ESRD population. Lower gastrointestinal bleeding refers to blood loss from a site in the gastrointestinal tract distal to the ligament of Treitz. It is usually suspected when a patient complains of hematochezia...
2018: Case Reports in Nephrology
https://www.readbyqxmd.com/read/29682205/ferric-citrate-and-ferric-edta-but-not-ferrous-sulfate-drive-amphiregulin-mediated-activation-of-the-map-kinase-erk-in-gut-epithelial-cancer-cells
#6
Nathalie M Scheers, Dora I A Pereira, Nuno Faria, Jonathan J Powell
Ferric chelates may be used as oral iron supplements or phosphate binders but both ferric citrate and ferric EDTA have been shown to promote tumor burden in murine models of colon cancer. Here we studied their effects on cancer cell growth, at typical supplemental iron levels encountered in the gastrointestinal tract (0.01-0.2 mM). Caco-2 and/or Hutu-80 cells were exposed to these forms of chelated iron or to ferrous sulfate and outcomes were assessed using cell proliferation assays, proteome profiler arrays, western blot, and ELISA...
March 30, 2018: Oncotarget
https://www.readbyqxmd.com/read/29672760/nutritional-status-and-survival-of-maintenance-hemodialysis-patients-receiving-lanthanum-carbonate
#7
Hirotaka Komaba, Takatoshi Kakuta, Takehiko Wada, Miho Hida, Takao Suga, Masafumi Fukagawa
Background: Hyperphosphatemia and poor nutritional status are associated with increased mortality. Lanthanum carbonate is an effective, calcium-free phosphate binder, but little is known about the long-term impact on mineral metabolism, nutritional status and survival. Methods: We extended the follow-up period of a historical cohort of 2292 maintenance hemodialysis patients that was formed in late 2008. We examined 7-year all-cause mortality according to the serum phosphate levels and nutritional indicators in the entire cohort and then compared the mortality rate of the 562 patients who initiated lanthanum with that of the 562 propensity score-matched patients who were not treated with lanthanum...
April 16, 2018: Nephrology, Dialysis, Transplantation
https://www.readbyqxmd.com/read/29671909/should-phosphate-management-be-limited-to-the-kdigo-kdoqi-guidelines
#8
Sangeet Dhillon-Jhattu, Stuart M Sprague
Hyperphosphatemia is a common complication of CKD. Prior to development of overt hyperphosphatemia, there are several adaptive mechanisms that occur to maintain normal phosphorus equilibrium in patients with CKD. These include an early and progressive rise in fibroblast growth factor 23 (FGF 23), followed by an increase in parathyroid hormone (PTH) with a decrease in 1,25-dihydroxyvitamin D (1,25 Vit D). Over the last 20 years, a large number of studies have shown that hyperphosphatemia is a strong predictor of adverse clinical outcomes including increased incidence of vascular calcification, cardiovascular disease, and all-cause mortality in both individuals with CKD as well as those with normal kidney function...
April 19, 2018: Seminars in Dialysis
https://www.readbyqxmd.com/read/29657783/research-on-preparation-of-phosphate-modified-animal-glue-binder-for-foundry-use
#9
Tian-Shu Wang, Wei-Hua Liu, Ying-Min Li
In this paper, three phosphates were used as modifiers to modify animal glue binder. The structural characteristics and thermal properties of animal glue binder treated with phosphates were studied by Fourier transform-infrared spectroscopy, gel permeation chromatography and derivative thermogravimetric analysis. The results showed that the modified animal glue binder had better sand tensile strength and lower viscosity than untreated animal glue binder. The best modification process was as follows: the optimal amount of sodium carbonate was 4 wt% to animal glue; the optimal weight ratio of the modifiers was sodium pyrophosphate : sodium tripolyphosphate : sodium hexametaphosphate : animal glue = 3 : 3 : 4 : 100, and the optimal reaction should be performed at 80°C for a reaction time of 120 min...
March 2018: Royal Society Open Science
https://www.readbyqxmd.com/read/29656600/long-term-efficacy-and-safety-of-sucroferric-oxyhydroxide-in-african-american-dialysis-patients
#10
Stuart M Sprague, Markus Ketteler, Adrian C Covic, Jürgen Floege, Viatcheslav Rakov, Sebastian Walpen, Anjay Rastogi
INTRODUCTION: Sucroferric oxyhydroxide (SFOH) is a non-calcium, iron-based phosphate binder that demonstrated sustained serum phosphorus (sP) control, good tolerability, and lower pill burden, vs. sevelamer carbonate ("sevelamer"), in a Phase 3 study conducted in dialysis patients with hyperphosphatemia. This analysis evaluates the efficacy and safety of SFOH and sevelamer among African American (AA) patients participating in the trial. METHODS: Post hoc analysis of a 24-week, Phase 3, open-label trial (NCT01324128) and its 28-week extension study (NCT01464190)...
April 15, 2018: Hemodialysis International
https://www.readbyqxmd.com/read/29629279/effects-of-education-on-low-phosphate-diet-and-phosphate-binder-intake-to-control-serum-phosphate-among-maintenance-hemodialysis-patients-a-randomized-controlled-trial
#11
Eunsoo Lim, Sunah Hyun, Jae Myeong Lee, Seirhan Kim, Min-Jeong Lee, Sun-Mi Lee, Ye-Sung Oh, Inwhee Park, Gyu-Tae Shin, Heungsoo Kim, Donald E Morisky, Jong Cheol Jeong
Background: For phosphate control, patient education is essential due to the limited clearance of phosphate by dialysis. However, well-designed randomized controlled trials about dietary and phosphate binder education have been scarce. Methods: We enrolled maintenance hemodialysis patients and randomized them into an education group (n = 48) or a control group (n = 22). We assessed the patients' drug compliance and their knowledge about the phosphate binder using a questionnaire...
March 2018: Kidney Research and Clinical Practice
https://www.readbyqxmd.com/read/29627829/effect-of-lanthanum-carbonate-on-all-cause-mortality-in-patients-receiving-maintenance-hemodialysis-a-meta-analysis-of-randomized-controlled-trials
#12
Fang Wang, Xiangxue Lu, Jingli Zhang, Ruifang Xiong, Han Li, Shixiang Wang
BACKGROUND/AIMS: Hyperphosphatemia is common in patients on hemodialysis. The efficacy of lanthanum carbonate (LC) in the treatment of hyperphosphatemia in these patients remains controversial. The objective of this meta-analysis was to evaluate the effect of LC on all-cause mortality in patients on maintenance hemodialysis. METHODS: We electronically searched the PubMed, EMBASE, and Cochrane Library databases for all randomized controlled trials (RCTs) comparing LC with other phosphate binders used in adult hemodialysis patients, including calcium carbonate, calcium acetate, and sevelamer...
March 29, 2018: Kidney & Blood Pressure Research
https://www.readbyqxmd.com/read/29617976/the-effects-of-tenapanor-on-serum-fibroblast-growth-factor-23-in-patients-receiving-hemodialysis-with-hyperphosphatemia
#13
Geoffrey A Block, David P Rosenbaum, Andrew Yan, Peter J Greasley, Glenn M Chertow, Myles Wolf
Background: Elevated serum fibroblast growth factor 23 (FGF23) is strongly associated with cardiovascular risk and mortality. Tenapanor, an inhibitor of gastrointestinal sodium/hydrogen exchanger isoform 3, decreased serum phosphate in a randomized, double-blind, placebo-controlled Phase 2 trial (ClinicalTrials.gov identifier NCT02081534) of patients receiving hemodialysis with hyperphosphatemia. Here, we report a secondary analysis of effects on serum FGF23 during that study. Methods: After 1-3 weeks of washout of phosphate binders, 162 patients were randomized to receive 4 weeks of treatment with placebo or one of six tenapanor regimens (3 or 30 mg once daily, or 1, 3, 10 or 30 mg twice daily)...
April 3, 2018: Nephrology, Dialysis, Transplantation
https://www.readbyqxmd.com/read/29594503/hyperphosphatemic-tumoral-calcinosis-caused-by-fgf23-compound-heterozygous-mutations-what-are-the-therapeutic-options-for-a-better-control-of-phosphatemia
#14
Debora Claramunt-Taberner, Aurélia Bertholet-Thomas, Marie-Christine Carlier, Frédérique Dijoud, Franck Chotel, Caroline Silve, Justine Bacchetta
BACKGROUND: Hyperphosphatemic familial tumoral calcinosis (HFTC) is a rare autosomal recessive disease caused by mutations in genes encoding FGF23 or its regulators, and leading to functional deficiency or resistance to fibroblast growth factor 23 (FGF23). Subsequent biochemical features include hyperphosphatemia due to increased renal phosphate reabsorption, and increased or inappropriately normal 1,25-dihydroxyvitamin D (1,25-D) levels. CASE-DIAGNOSIS/TREATMENT: A 15-year-old girl was referred for a 1...
March 28, 2018: Pediatric Nephrology: Journal of the International Pediatric Nephrology Association
https://www.readbyqxmd.com/read/29582226/a-long-term-feed-supplementation-based-on-phosphate-binders-in-feline-chronic-kidney-disease
#15
E Biasibetti, E Martello, M Bigliati, I Biasato, T Cocca, N Bruni, M T Capucchio
Chronic kidney disease (CKD) is a very common disorder in elderly cats. A proper renal diet represents the most efficient therapeutic intervention to improve survival and life quality in feline patients with 3 and 4 International Renal Interest Society (IRIS) stages. Twenty cats were selected in this study. Ten were administered the dietary supplementation for 360 days and the other ten, whose owners did not give consent for any supplemental therapies apart from the renal diet, were selected from a clinical database and used as control group...
March 26, 2018: Veterinary Research Communications
https://www.readbyqxmd.com/read/29580635/prevention-and-treatment-of-hyperphosphatemia-in-chronic-kidney-disease
#16
REVIEW
Marc G Vervloet, Adriana J van Ballegooijen
Hyperphosphatemia has consistently been shown to be associated with dismal outcome in a wide variety of populations, particularly in chronic kidney disease (CKD). Compelling evidence from basic and animal studies elucidated a range of mechanisms by which phosphate may exert its pathological effects and motivated interventions to treat hyperphosphatemia. These interventions consisted of dietary modifications and phosphate binders. However, the beneficial effects of these treatment methods on hard clinical outcomes have not been convincingly demonstrated in prospective clinical trials...
March 23, 2018: Kidney International
https://www.readbyqxmd.com/read/29566839/cost-effectiveness-of-first-line-sevelamer-and-lanthanum-versus-calcium-based-binders-for-hyperphosphatemia-of-chronic-kidney-disease
#17
COMPARATIVE STUDY
Steven Habbous, Sebastian Przech, Janet Martin, Amit X Garg, Sisira Sarma
BACKGROUND: Phosphate binders are used to treat hyperphosphatemia among patients with chronic kidney disease (CKD). OBJECTIVES: To conduct an economic evaluation comparing calcium-free binders sevelamer and lanthanum with calcium-based binders for patients with CKD. METHODS: Effectiveness data were obtained from a recent meta-analysis of randomized trials. Effectiveness was measured as life-years gained and translated to quality-adjusted life-years (QALYs) using utility weights from the literature...
March 2018: Value in Health: the Journal of the International Society for Pharmacoeconomics and Outcomes Research
https://www.readbyqxmd.com/read/29543529/in-vitro-aflatoxin-b-1-binding-by-the-cell-wall-and-1%C3%A2-3-%C3%AE-d-glucan-of-baker-s-yeast
#18
Mohammad Hadi Aazami, Mohammad Hasan Fathi Nasri, Mohsen Mojtahedi, Shahla Roudbar Mohammadi
The aim of this study was to evaluate the ability of heat-killed baker's yeast (HKBY), the cell wall of baker's yeast (CWBY), and cell wall (1→3)-β-d-glucan of baker's yeast (BGBY) to bind aflatoxin B1 (AFB1 ) in phosphate-buffered saline (PBS) spiked with 0.5 μg/mL AFB1 . Baker's yeast ( Saccharomyces cerevisiae) was heat killed by autoclaving at 121°C for 10 min. The cell wall was physically extracted, and (1→3)-β-d-glucan was extracted by a modified method. The concentration of AFB1 was determined by high-performance liquid chromatography after exposure to binders for three contact times, 30 min, 5 h, and 24 h, at room temperature...
March 16, 2018: Journal of Food Protection
https://www.readbyqxmd.com/read/29536389/rationale-design-and-characteristics-of-a-trial-to-evaluate-the-new-phosphate-iron-based-binder-sucroferric-oxyhydroxide-in-dialysis-patients-with-the-goal-of-advancing-the-practice-of-e-b-m-episode
#19
Yoshitaka Isaka, Hideki Fujii, Yoshihiro Tsujimoto, Satoshi Teramukai, Takayuki Hamano
BACKGROUND: In dialysis patients, mortality risk due to cardiovascular diseases is remarkably high and prognosis is poor; coronary artery calcification is considered one of the major contributing factors. It is known that hyperphosphatemia is associated with coronary artery calcification. Therefore, controlling serum phosphate level and thereby mitigating vascular calcification could improve the poor prognosis of dialysis patients. However, the optimal phosphate level in dialysis patients remains unknown; hence, this study was planned to compare the effects of two types of non-calcium-based phosphate binders, and examine the effect of strict control of phosphate on coronary artery calcification...
March 13, 2018: Clinical and Experimental Nephrology
https://www.readbyqxmd.com/read/29532306/calcimimetics-versus-parathyroidectomy-what-is-preferable
#20
REVIEW
M Rroji, G Spasovski
Secondary hyperparathyroidism (SHPT) is common among patients with end-stage renal disease (ESRD). SHPT is associated with high-turnover bone disease, interstitial and vascular calcifications, cardiovascular morbidity and mortality. The pharmacological management of SHPT has progressed in recent years. The introduction of targeted therapies, such as selective vitamin D receptors activators and calcium-sensing receptor modulators, offers an increased opportunity to adequately control elevated parathyroid hormone (PTH), especially in patients with chronic kidney disease under dialysis treatment...
March 12, 2018: International Urology and Nephrology
keyword
keyword
119306
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"